NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
Henrik Gürtler Chairman of the Board
Director Kurt Anker Nielsen Vice Chairman of the Board
Lena Olving Deputy CEO and Chief Operating Officer, Saab AB (Sweden)
Jørgen Buhl Rasmussen President and CEO, Carlsberg A/S
Agnete Raaschou-Nielsen Chairman of the Board, Brdr. Hartmann A/S
Mathias Uhlén Professor, the Royal Institute of Technology (Sweden)
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
Søren Jepsen Manager, Regulatory Affairs
Lars Bo Køppler Technician
Ulla Morin Laboratory Technician
Steen Riisgaard President and CEO
Per Falholt Executive Vice President, Research & Development and CSO
Benny D. Loft Executive Vice President and CFO
Peder Holk Nielsen Executive Vice President, Enzyme Business
Thomas Nagy Executive Vice President, Stakeholder Relations and COS
Thomas Videbæk Executive Vice President, BioBusiness
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
1. Report of the Board of Directors 2. Presentation and approval of the audited annual report 3. Resolution on distribution of profit in accordance with the approved annual report 4. Approval of remuneration of the Board of Directors for the present year 5. Election of Chairman 6. Election of Vice Chairman 7. Election of other board members 8. Election of auditor 9. Proposals from the Board of Directors: 9a. Authorization to reduce stock capital 9b. Authorization to chairperson of meeting 10.Any other business
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
2012: STRONGER THROUGH CHALLENGING TIMES Organic sales growth of 4% - below long-term target Good development in earnings and EBIT margin Strong year for Household Care and Animal feed Awarded gold in Dow Jones Sustainability Index New enzyme facility opened in Nebraska, USA Start of commercial production of biomass-based biofuels Significant partnerships: Syngenta, BASF, Beta Renewables, Natural Industries Inc.
WORKING TOGETHER TOWARD COMMON GOALS What is happening in the world What are the trends? What do our customers want?
CHAMPIONING THE BIOBASED SOCIETY
CUSTOMER PARTNERSHIPS Novozymes entered into a number of partnerships in 2012 through Acquisitions Distribution agreements Exclusive contracts Common denominator: technology and business development
CUSTOMER PARTNERSHIPS SUSTAINABLE INNOVATION Novozymes awarded Business Partner of the Year for the fifth year in a row
CUSTOMER PARTNERSHIPS ACQUISITION OF COMPLEMENTARY TECHNOLOGY Natural Industries Inc. We can leverage Novozymes platform and competences to create more value of acquired technologies
CUSTOMER PARTNERSHIPS NOVOZYMES TECHNOLOGY IN DEMAND
CUSTOMER PARTNERSHIPS DRIVING THINGS FORWARD TOGETHER
INTERNAL PARTNERSHIPS
SALES AND MARKETS FOR NOVOZYMES DKK 11.2 billion +7% in DKK +4% organic growth
ENZYME BUSINESS +7% in DKK DKK 10 billion +3% organic growth 91% of group turnover Good sales growth for enzymes to the Household Care and animal feed industries Challenging year for bioenergy
BIOBUSINESS +5% in DKK +10% organic growth Positive development within microorganisms for BioAgriculture
INCOME STATEMENT +4% Sales growth +17% EBIT growth 24,4% EBIT margin +10% Net profit growth
BALANCE SHEET 63% equity ratio DKK 1,429 million in Net-interest-bearing-debt DKK 1.4 billion to shareholders
SUSTAINABILITY All targets met, except water efficiency Strong development in CO 2 efficiency Fatal occupational accident
2013 EXPECTATIONS 5-8% organic sales growth 4-7% EBIT growth ~24 EBIT margin ~20% ROIC
2013 SUSTAINABILITY TARGETS Compared with 2005 42% energy efficiency 50% reduction in CO 2 -emission per kilo of product 35% water efficiency Reduce CO 2 -emissions by 50 million tons through customer application of solutions
UPDATED LONG-TERM TARGETS Average organic sales growth > 10% EBIT margin > 24% ROIC > 22% The average organic sales growth target is expected to be reached from 2015 and onward, following a ramp-up from current levels
MANAGEMENT REMUNERATION POLICY AND BOARD FEES Salary package for Executive Management comprises Fixed base salary Cash bonus, which takes into account annual and individual targets Stock-based incentive program, which takes into account longterm targets Total remuneration to the Board of Directors in 2011 was DKK 5.9 million An unchanged basic fee of DKK 416,666 is proposed
CORPORATE GOVERNANCE The collaboration between the Board of Directors and Executive Management was once again assessed to be generally positive in 2012 Novozymes follows the new Danish corporate governance recommendations, based on the principle comply or explain Novozymes complies with 72 of the 79 recommendations, and explains its position on the remaining 7
DISTRIBUTION OF PROFIT 2012 dividende = DKK 2.20 per share Increase of DKK 0.30. (+16% on 2012-dividend) 34.1 % of net profit (DKK 687 million) It is proposed that the remaining profit be carried forward (DKK 1,329 million)
SHARE PRICE DEVELOPMENT 250,00 Nov. 17 th 2000 Feb. 26 th 2013 200,00 150,00 100,00 50,00 0,00
END OF REVIEW End of review of 2012 Read more in The Novozymes Report
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
REDUCTION OF THE COMPANY S SHARE CAPITAL The Board of Directors proposes reduction of the Company s share capital by cancellation of part of its holding of its treasury B shares. The Board proposes that the Company s share capital shall be reduced by DKK 10,600,000 from DKK 542,512,800 to DKK 531,912,800. The total share capital will hereafter amount to DKK 639,400,000.
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
Henrik Gürtler Chairman of the Board
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
Director Kurt Anker Nielsen Vice Chairman of the Board
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
Lena Olving Deputy CEO and Chief Operating Officer, Saab AB (Sweden)
Agnete Raaschou-Nielsen Chairman of the Board, Brdr. Hartmann A/S
Jørgen Buhl Rasmussen President and CEO, Carlsberg A/S
Mathias Uhlén Professor, the Royal Institute of Technology (Sweden)
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
Henrik Gürtler, chairman Kurt Anker Nielsen, vice chairman Agnete Raaschou-Nielsen Lena Olving Jørgen Buhl Rasmussen Mathias Uhlén
New employee elected members Lars Bo Køppler, Technician Lena Bech Holskov, Safety Adviser Anders Hentze Knudsen, Senior Operator
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
AUTHORIZATION TO REDUCE STOCK CAPITAL The Board of Directors proposes reduction of the Company s share capital by cancellation of part of its holding of its treasury B shares. The Board proposes that the Company s share capital shall be reduced by DKK 10,600,000 from DKK 542,512,800 to DKK 531,912,800. The total share capital will hereafter amount to DKK 639,400,000.
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
AUTHORIZATION TO CHAIRPERSON OF MEETING The chairperson of the Annual Shareholders Meeting is authorized to make such alterations to the Articles of Association, including the numbering, as may ensue from the resolutions passed at the Annual Shareholders Meeting. The chairperson is further authorized to make such alterations and additions to the resolutions and in the notification to the Danish Business Authority as may be required in connection with registration of the adopted alterations.
Any other business
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
STEEN RIISGAARD
NOVOZYMES GENERALFORSAMLING BALLERUP SUPER ARENA 2013
WELCOME PEDER HOLK NIELSEN
THE NEW TEAM
NOVOZYMES ANNUAL SHAREHOLDERS' MEETING BALLERUP SUPER ARENA 2013
GOODBYE AND THANK YOU FOR COMING! Buses heading for Ballerup station will leave from just outside the hall from 18:30, with the last departure at approx. 19:45 Next year s Annual Shareholders Meeting will take place on February 26, 2014